Abstract
A prospective randomized study to evaluate the effect of adjuvant intrapleural OK-432 immunotherapy after resection of lung tumor was conducted in 93 patients with primary lung cancer. Among them, 46 patients had had intrapleural OK-432 injection, 47 had not. In the meantime, serial measurements of serum immunosuppressive acidic protein, of serum interleukin-2 receptor and of the sub-population of the peripheral blood cells and lymphocytes were performed in all these patients. Patient characteristics in these two groups (sex, age, histological type, pathological stage, type of operation, and performance status) were compatible. The results showed that adjuvant intrapleural OK-432 injection after resection had no beneficial effect on a patient's survival time. Patients who received intrapleural OK-432, had an increase in blood leukocytes, granulocytes and monocytes and serum immunosuppressive acidic protein level. But the cell numbers of total T cells, suppressor/cytoxic cells, helper/inducer cells and natural killer cells of peripheral blood were decreased in the OK-432 positive group. Over half of the patients had transient 1- or 2-day febrile reactions after intrapleural OK-432 injection. It was concluded that neither clinical observation nor immunological monitoring of peripheral blood could demonstrate a beneficial effect from intrapleural OK-432 immunotherapy after complete resection of the tumor.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ruckdeschel JC (1988) Management of malignant pleural effusion: an overview. Semin Oncol [Suppl 3]: 15–24
Luh KT, Yang PC, Kuo SH, Chang DB, Yu CJ, Lee LN (1992) Comparison of OK-432 and mitomycin C pleurodesis for malignant pleural effusion caused by lung cancer: a randomized trial. Cancer 69: 674
McKneally ME, Maver C, Kausel HW, Alley RD (1976) Regional immunotherapy with intrapleural BCG for lung cancer: surgical considerations. J Thorac Cardiovasc Surg 72: 333
Jansen HM, The TH, Orie NGM (1980) Adjuvant immunotherapy with BCG in squamous cell bronchial carcinoma. Thorax 35: 781
Mountain CE, Gail MH (1981) Surgical adjuvant intrapleural BCG treatment for stage 1 non-small cell lung cancer: preliminary report of the National Cancer Institute Lung Cancer Study Group. J Thorac Cardiovasc Surg 82: 649
Bakker W, Nijhuis-Heddes JMA, Wever AMJ, Brutel De LA, Riviere A, Van Der Velde EA, Dijkman JH (1981) Postoperative intrapleural BCG in lung cancer: lack of efficacy and possible enhancement of tumor growth. Thorax 36: 870
Oshimi K, Kano S, Takaku F, Okumura K (1980) Augmentation of mouse natural killer cell activity by a streptococcal preparation OK-432. J Natl Cancer Inst 65: 1265
Hojo H, Hashimoto Y (1981) Cytotoxic cells induced in tumor-bearing rats by a streptococcus preparation (OK-432). Gann 72: 692
Torisn M, Katano M, Kimura Y, Itoh H, Takesue M (1983) New approach to management of malignant ascites with a streptococcal preparation OK-432. I. Improvement of host immunity and prolongation of survival. Surgery 93: 357
Katano M, Torisu M (1983) New approach to management of malignant ascites with a streptococcal preparation OK-432. II. intraperitoneal inflammatory cell-mediated tumor cell destruction. Surgery 93: 365
Hayashi Y, Torisu M (1990) New approach to management of malignant ascites with streptococcal preparation OK-432. III. OK-432 attracts natural killer cells through a chemotactic factor released from activated neutrophils. Surgery 107: 74
Nagao K (1982) Studies on treatment of pleural carcinomatosis, with special reference to effect of OK-432 Chiba Med J 58: 345
Watanabe Y, Iwa T (1984) Clinical value of immunotherapy for lung cancer by the streptococcal preparation OK-432. Cancer 53: 248
Tamura K, Shibata Y, Matsuda Y, Ishida N (1981) Isolation and characterization of an immunosuppressive acidic protein from ascitic fluids of cancer patients. Cancer Res 41: 3244
Marino P, Cugno M, Preatoni A, et al. (1990) Increased levels of soluble interleukin-2 receptors in serum of patients with lung cancer. Br J Cancer 61: 434
Yang SC, Owen-Schaub L, Mendiguren-Rodriguez A, et al (1990) Combination immunotherapy for non-small cell lung cancer: results with interleukin-2 and tumor necrosis factor-α. J Thorac Cardiovasc Surg 99: 8
Ruckdeschel JC, Codish SD, Stranahan A, McKneally MF (1972) Postoperative empyema improves survival in lung cancer: documentation and analysis of a natural experiment. N Engl J Med 287: 1013
Schmid K, Binetta JP, Kamiyama S, Pfester V, Takahashi S (1962) Studies on structure of α 1-glycoprotein. III. Polymorphism of α1-acid glycoprotein and the partial resolution and characterization of its variants. Biochemistry 1: 959
Shibata Y, Tamura K, Ishida N (1984) Cultured human monocytes, granulocytes and monoblastoid cell line (THP-1) synthesized and secrete immunosuppressive acidic protein (a type of α1-acid glycoprotein). Microbiol Immunol 28: 99
Ushida A, Micksche M (1983) Lysis of fresh human tumor cells by autologous peripheral blood lymphocytes and pleural effusion lymphocytes activated by OK-432. J Natl Cancer Inst 71: 673
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lee, YC., Luh, SP., Wu, RM. et al. Adjuvant immunotherapy with intrapleuralStreptococcus pyogenes (OK-432) in lung cancer patients after resection. Cancer Immunol Immunother 39, 269–274 (1994). https://doi.org/10.1007/BF01525991
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01525991